Aquilon Pharma, originally founded as a spinout from the University of Liège, Belgium, has an innovative portfolio of new formulations that significantly improves the efficacy of inhaled drugs for asthma and COPD (Chronic Pulmonary Obstructive disorder). Strongly focused on precision and quality, the company's dry powder and nebulized formulations can also be used in developing existing non-inhaled drugs as inhalable.

Aquilon Pharma has ordered PreciseInhale[®], ISAB's high-precision aerosol R&D system, plus its Nose-Only and the unique Intratracheal Exposure Modules. The total order is worth 292 KEUR.

ISAB CEO Manoush Masarrat: "We are pleased to welcome a fellow pioneer in next-generation inhalation technology as new customer. We know how deeply Aquilon Pharma value precision and efficacy as key drivers for better treatment and care for patients, and we're proud that PreciseInhale[® ]will be playing an important role in helping them achieve that."

Aquilon Pharma CEO Paul MAES: "Aquilon is happy to acquire the PreciseInhale[®] equipment. It will be a great opportunity to work, together with highly experienced colleagues from the University, on innovative respiratory medicine research. Through this unique technology we will be able to move forward and extend the portfolio of our products in development. Aquilon intends to address all the challenges existing in the field of lung disease treatments and proposes drug products that are environment-friendly, easy to use and which allow a better lung deposition. Aquilon will carry out three clinical studies in 2021 to finalize its research. The company is today launching a 20 MEURO fund-raising campaign to finance its pre-commercialization projects."